Sherry Korczynski sold $46k of AQST
Chief Commercial Officer at Aquestive Therapeutics, Inc.. 8,750 shares at an average of $5.22, traded Sep 9, 2026, filed Sep 11, 2026.
Score components
- +15RoleOfficer
- +6Trade size$46k at market
- 0Share of holdings soldSold 3.6% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001214659-26-011596, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | MOption exercise Common Stock10b5-1 | +8,750 | $2.65 | $23k | 244,439 | 31 d ago |
| Sep 9, 2026 | SOpen-market sale Common Stock10b5-1 | -8,750 | $5.22 | $46k | 235,689 | 31 d ago |
| Sep 9, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -8,750 | $0.00 | $0 | 26,250 | 31 d ago |
Related signals
Other insiders at Aquestive Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Aquestive Therapeutics, Inc. | Daniel Barber President and CEO | $120k 25,000 shares | -4% | |
| 40Moderate | AQSTsell Aquestive Therapeutics, Inc. | Cassie Jung Chief Operating Officer | $214 44 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.